Company Overview
Snapshot
Founded in January 2015, NANOSONO operates with 11–50 employees and has raised $16 million across five funding rounds from two investors. In December 2022, the company signed a strategic agreement with Gadot Group, which included an investment and plans to build infrastructure for NANOSONO's antimicrobial technology.
Business overview
NANOSONO is a biotechnology company that has developed an antimicrobial platform capable of instantly and continuously destroying bacteria on various surfaces. Its core technology transforms materials into an "antimicrobial firewall" using nanotechnology, providing permanent, active protection without the need for re-application. The company's always-on antimicrobial shield can be integrated into a wide range of applications, serving markets in industrial technologies, healthcare, and life sciences, with specific applications in medical devices, pharmaceuticals, and coatings.
Strategic signal
In December 2022, NANOSONO secured a strategic agreement with Gadot Group, a chemical production and logistics company, which included a $2 million investment and a commitment to build production infrastructure for. This partnership signals strong commercial validation and a clear path to scaling production and market penetration for its antimicrobial solutions, particularly in industrial and clinical environments.
Log in to access full profile ›Company Intelligence Q&A
- What significant strategic partnership did NANOSONO establish in late 2022?
- In December 2022, NANOSONO signed a strategic agreement with Gadot Group, a chemical production and logistics company. This partnership included a $2 million investment from Gadot Group and plans to build the necessary infrastructure and production line for NANOSONO's antimicrobial technology.
- What is the core technology developed by NANOSONO?
- NANOSONO develops an antimicrobial platform utilizing nanoparticles made of zinc oxide and copper oxide, known as Quactiv. This technology allows surfaces to instantly and continuously destroy bacteria, providing permanent protection without re-application.
- What markets is NANOSONO targeting with its antimicrobial solutions?
- NANOSONO is targeting various markets globally, including the US, Europe, China, and India. The company is expanding its applications beyond paint to clinical environments, including bed sheets, surgical drapes, facemasks, and bandages, and exploring future applications in coatings for stone and marble surfaces.
- What was the total capital raised by NANOSONO?
- NANOSONO has raised $16 million across five funding rounds.
- What was a key partnership formed by NANOSONO in December 2021?
- In December 2021, NANOSONO entered into a cooperation agreement with Turkish company ODAS. This partnership involved ODAS investing in NANOSONO's antibacterial and antiviral technologies and jointly building a factory in Turkey to produce antibacterial fabrics and textiles for markets in Israel, Asia Pacific, and Europe.